2-吗啉甲基苯甲醛 | 736991-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-吗啉甲基苯甲醛
• 英文名称: 2-(morpholinomethyl)benzaldehyde
• 英文别名: 2-(morpholin-4-ylmethyl)benzaldehyde
• CAS: 736991-21-2
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD07782412
• 分子量: 205.257
• InChiKey: YPZNTOVVELIJGI-UHFFFAOYSA-N

物化性质

• 熔点：
  67 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-吗啉甲基苯甲醛 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-cyclobutyl-3,4-dimethoxy-N-(2-(morpholinomethyl)benzyl)benzenesulfonamide
  参考文献：
  名称：

  Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

  摘要：

  While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound.

  DOI：

  10.1080/14756366.2017.1347784
• 作为产物：
  描述：

  2-溴溴苄 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 2.0h， 生成 2-吗啉甲基苯甲醛
  参考文献：
  名称：

  Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

  摘要：

  While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound.

  DOI：

  10.1080/14756366.2017.1347784

文献信息

• [EN] IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-F] [1, 2, 4] TRIAZIN-4-AMINE UTILISÉS EN TANT QU'AGONISTES DE TLR7
  申请人：BEIGENE LTD

  公开号：WO2020160711A1

  公开（公告）日：2020-08-13

  Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

  披露的是一种咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐，用作TLR7激动剂，以及包含该化合物的药物组合物。还披露了一种使用咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐作为TLR7激动剂来治疗癌症的方法。
• Catalyst-free photodecarbonylation of <i>ortho</i>-amino benzaldehyde
  作者：Jingwei Zhou、Lamei Li、Songping Wang、Ming Yan、Wentao Wei

  DOI：10.1039/d0gc01256d

  日期：——

  strategy, we broke this consensus and discovered a catalyst-free photodecarbonylation of the aldehyde group. It revealed that decarbonylation can be easily achieved with visible light irradiation by introducing a tertiary amine into the ortho-position of the aldehyde group. A diverse array of tertiary amines is tolerated by our photodecarbonylation under mild conditions. Furthermore, the (QM) computations

  几乎共识是，醛基（–CHO）的脱羰不仅需要通过过渡金属催化剂来介导，而且还需要严格的反应条件（高温和长反应时间）。在这项工作中，受“基于构象选择性的”设计策略的启发，我们打破了这一共识，并发现了醛基的无催化剂光脱羰基。它表明，脱羰基化可以用可见光照射能够容易地实现通过引入叔胺到邻醛基的-位置。在温和条件下，我们的光脱羰基化可以耐受各种各样的叔胺。此外，在精心设计的特殊底物上进行机理和实验的（QM）计算表明，我们的光脱羰基取决于醛基和叔胺的构象特异性，并通过异常的[1,4] -H位移和随后的[1,3] -H移位。
• Identification and application of threonine aldolase for synthesis of valuable α-amino, β-hydroxy-building blocks
  作者：Mathieu Ligibel、Charles Moore、Robert Bruccoleri、Radka Snajdrova

  DOI：10.1016/j.bbapap.2019.140323

  日期：2020.2

  key step to access the synthesis of our target API. Beyond this specific application, the aldolase was purified, characterized and the substrate scope of this enzyme further investigated. A number of enzymatic reactions were scaled-up and the products recovered to assess the diastereoselectivity and scalability of this asymmetric synthetic approach towards β-hydroxy α-amino acid chiral building blocks

  手性β-羟基α-氨基酸的结构基序是有趣的，并且常见的合成子存在于多种API和候选药物中。为了获得这些手性结构单元，需要多步化学合成或使用苏氨酸醛缩酶，其催化醛和甘氨酸之间的醛缩反应。已经利用生物信息学工具鉴定了来自Vanrija humicola的编码苏氨酸醛缩酶的基因，并随后从大肠杆菌发酵中制备了其重组形式。我们计划将这种酶实施为访问目标API合成的关键步骤。除此特定应用外，还对醛缩酶进行了纯化，表征并进一步研究了该酶的底物范围。
• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。